Wheeler Bio
Preclinical-to-Clinical Mammalian Biologics Development and Manufacturing – CDMO
Goals & Objectives
Wheeler Bio is a VC-backed mammalian-focused CDMO with a proprietary mAb platform called Portable CMC™, which bridges discovery and clinical manufacturing to reduce development timelines, as well as mitigate the cost and risk associated with bringing novel therapies to the clinic. It needed a go-to-market strategy and brand launch.
Strategic Approach
Wheeler Bio’s Portable CMC™ platform uniquely bridges the gap between preclinical work and scale-up. That’s Nice used speaking engagements and sponsorships to build brand awareness around this concept. The go-to-market strategy centered on the experienced senior team Wheeler had drawn from leading CDMOs, and the accessibility of its new Oklahoma facilities with state-of-the-art technology.
Meeting & Exceeding KPIs
Moving into year three of its relationship with That’s Nice, Wheeler Bio has gained significant industry traction. This has not only allowed them to forge partnerships with industry-leading discovery and testing companies, but also given its financial backers confidence in the company’s future and profitability as it continues to invest in growth and scale.
